We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Olympus Signs Licensing Agreements with Omnyx

By LabMedica International staff writers
Posted on 11 Mar 2010
Olympus America Inc. More...
(Center Valley, PA, USA) has signed a nonexclusive worldwide licensing agreement with Omnyx, LLC, (Pittsburgh, PA; and Piscataway, NJ, USA)--a joint venture of GE Healthcare (Fairfield, CT, USA) and the University of Pittsburgh Medical Center (UPMC; Pittsburgh, USA).

The agreement permits Omnyx to access the extensive portfolio of Olympus America patents in the field of virtual microscopy and digital pathology. The patents involved in the licensing agreement cover software and technology related to creating, storing, and delivering virtual microscopy images. The specific terms and conditions of the agreement are not being made public by the two companies.

Virtual microscope slides enable professionals to review biopsies and other pathology images without handling traditional glass slides, and allow doctors to share high-resolution digital microscope images over the Internet for remote pathology consultation.

The technology also has the potential to aid hospitals in moving to comprehensive patient Electronic Medical Record (EMR) systems--a transition that has already started in some areas of the world.

According to a 2010 report published by Laboratory Economics, US$13.2 billion was spent in anatomic pathology testing in the United States during 2008. The patented technologies will help deliver valuable images to doctors, streamline the review process, improve speed of reporting, save substantial expense, and enhance patient care.

Olympus works collaboratively with its customers and affiliates worldwide to leverage Research and Development (R&D) investment in precision technology and manufacturing processes across diverse business lines. These include advanced clinical, research, and educational microscopes and clinical digital imaging systems.

Related Links:

Olympus America Inc.
Omnyx, LLC
GE Healthcare
University of Pittsburgh Medical Center



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Hematology Consumables
Bioblood Devices
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.